Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor

Nature Immunology

Volumn 8, Issue 12, 2007, Pages 1337-1344

  Walzer, Thierry ^a   Chiossone, Laura ^a   Chaix, Julie ^b   Calver, Andrew ^c,d   Carozzo, Claude ^e,f   Garrigue Antar, Laure ^e,f   Jacques, Yannick ^a   Baratin, Myriam ^a   Tomasello, Elena ^a   Vivier, Eric ^a,g  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITÉ DE LYON   (France)

^d VETAGRO SUP   (France)

^e INSTITUT DE BIOLOGIE   (France)

^f UNIVERSITÉ DE NANTES   (France)

^g HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOPHOSPHOLIPID; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL HOMING; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE RECIRCULATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REGULATORY MECHANISM; STEADY STATE;

EID: 36248966560     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni1523     Document Type: Article

References (51)

1. Bottino, C., Moretta, L. & Moretta, A. NK cell activating receptors and tumor recognition in humans. Curr. Top. Microbiol. Immunol. 298 175-182 (2006).
2. Newman, k.C. & Riley, E.M. Whatever turns you on; accessofy-cell-dependent activation of NK cells by pathogens. Nat. Rev. Immunol. 7, 279-291 (2007).
3. Lodoen, M.B. & Lanier, L.L. Natural killer cells as an initial defense against pathogens. Curr. Opin: Immunol. 18, 391-398 (2006).
4. Huntington, N.D., Vosshenrich, C.A. & Di Santo, J.P. Developmental pathways that generate -natural-killer-celf diversity in mice and humans. Nat. Rev. Immunol. 7, 703-714 (2007).
5. Stewart, C.A. et al. Germ-line and rearranged Tcrd transcription distinguish bona fide NK cells and NK-like γδ T cells. Eur. J. Immunol. 37, 1442-1452 (2007).
6. Gregoire, C. et al. The trafficking of natural killer cells. Immunol. Rev. (in the preis).
7. Hokeness, K.L., Kuziel, W.A., Biron, C.A. & Salazar-Mother, TP. Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-γM/β-induced inflammatory responses and antiviral defense in liver. J. Immunol. 174, 1549-1556 (2005).
8. Thapa, M., Kuziel, W.A. & Carr, D.J. Susceptibility of UCCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization. J. Virol. 81, 3704-3713 (2007).
9. Ajuebor, M.N. et al. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine Tcell-mediated hepatitis. Am. J. Pathol. 170, 1975-1988 (2007).
10. Khan, I.A. et al. CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pothog 2, e49 (2006).
11. 1 priming. Nat. Immunol. 5, 1260-1265 (2004).
12. Jiang, D. et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J. Clin. Invest. 114, 291-299 (2004).
13. Huang, D. et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 20, 896-905 (2006).
14. Yu, Y.R. et al. Defective antitumor responses in CX3CR1 -deficient mice. Int. J. Cancer 121, 316-322 (2007).
15. Lavergne, E. et al. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res. 63, 7468-7474 (2003).
16. Wald, O. et al. IFN-γ acts on T cells to induce NK cell mobilization and accumulation in target organs. J. Immunol. 176 4716-4729 (2006).
17. Inngierdingen, M Damaj, B. & Maghazachi, A.A. Expression -and regulation of chemokine receptors in human natural killer cells. Blood 97 367-375 (2001).
18. + NKTcells patrolling liver sinusoids. PLoS Biol. 3, e113 (2005).
19. Cyster, J.G. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu. Rev. Immunol. 23, 127-159 (2005).
20. Rosen, H. & Goetzl, E.J. Sphingosine 1-phosphate and its receptors: An autocrine and paracrine network. Nat. Rev. Immunol. 5, 560-570 (2005).
21. Rosen, H., Sanna, M.G., Cahalan, S.M. & Gonzalez-Cabrera, P.J. Tipping the gate- keeper: SIP regulation of endLqthelial banver function. Trends, Immunol. 28, 102-107 (2007).
22. Brinkmann, V. Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115, 84-105 (2007). a
23. Schwab, S.R. et al. Lymphocyte sequestration through SIP Iyase inhibition and disruption of S1P gradients. Science 309, 1735-1739 (2005).
24. Matloubian, M. et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355-360 (2004).
25. Wei, S.H. et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of meoullary T cells to lymphatic sinuses. Nat. Immunol. 6, 1228-1235 (2005).
26. Terai, K. et al. Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS. Neuroscience 116 1053-1062 (2003).
27. Im, D.S. et al. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J. Biol. Chem. 275, 14281-14286 (2000).
28. Jaillard, C. et al. Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 25, 1459-1469 (2005).
29. Walzer, T. et al. Identification, activation, and selective in vivo ablation of mouse NK cells.via NKp46. Proc. Natl.-Acad. Sci. USA 104, 3384-3389 (2007).
30. + to post-genomics meta-analyses. Curr. Opin. Immunol. 19, 365-372 (2007).
31. Goetzl, E.J. & Rosen, H. Regulation of immunity by lysosphingolipids and their G protein-coupled receptors. J. Clin. Invest, 114, 1531-1537 (2004).
32. Lucas, M., Schachterle, W., Oberle, K., Aichele, P. & Diefenbach, A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26, 503-517 (2007).
33. Mortier, E. et al. Soluble interleukin-15 receptor α (IL-15R α)-sushi as a selective and potentagonist of IL-15 action through IL-15Rβ/γ. Hyperagonist IL-15 x IL-15Rα fusion proteins. J. Biol. Chem. 281, 1612-1619 (2006).
34. Hayakawa, Y. & Smyth, M.J. CD27 dissects nature NK cells into two subsets with distinct reponsiveness and migratory capacity, J. Immunol. 176, 1517-1524 (2006).
35. Goetzl, E.J., Kong, Y. & Mei, B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T-cells from apoptosis in association with suppression of Box. J lmmunol. 162, 2049-2056 (1999).
36. Wang, W., Graeler, M.H. & Goetzl, E.J. Physiological sphingosine 1-phosphate requirement for optimal activity of mouse, CD4+ regulatory T Cells. FASFB J. 18, 1043-1045 (2004).
37. Graeler, M. & Goetzl, E.J. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic Tcells. FASEB J. 16, 1874-187 (2002).
38. Kveberg, L., Bryceson, Y., Inngjerdingen, M., Rolstad, 13. & Maghazachi, A.A. Sphingosine 1 phosphate induces the chemotaxis of human natural killer cells. Role for heterotrimeric G proteins and phosphoinositide 3 kinases. Eur J. Immunol. 32, 1856-1864 (2002).
39. Wang, J., Xu, J.W., Zhang, W.C., Wei, H.M. & Tian, Z.G. TLR3 ligand-induced accumulation of activated splenic natural killer cells into liver. Cell. Mol. Immunot. 2, 449-453 (2005).
40. Mandala, S. et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346-349 (2002).
41. Chen, S., Kawashima, H., Lowe, J.B., Lanier, L.L. & Fukuda, M. Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J. Exp. Med. 202, 1679-1689 (2005).
42. Bajenoff, M. et al. Natural killer cell behavior in lymph nodes revealed by static and real-time imaging. J. Exp. Med. 203, 619-631 (2006).
43. Kelly, P., Casey, P.J. & Meigs, T.E. Biologic functions of the G12 subfamily of hetetotrimeric G proteins: Growth, migration, and metastasis. Biochemistry 46, 6677-6687 (2007).
44. 5 inhibits oligodendrocyte progenitor migration. FASEB J. 21, 1503-1514 (2007).
45. Hanessian, S., Charron, G., Billich, A. & Guerini, D. Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. Bioorg. Med. Chem. Lett. 17, 491-494 (2007).
46. Freud, A.G. & Caligiuri, M.A. Human natural killer cell development. Immunol. Rev. 214, 56-72 (2006).
47. Ferlazzo, G. et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 172, 1455-4462 (2004).
48. Vaessen, L.M., van Besouw, N.M., Mol, W.M., Ijzermans, J.N. & Weimar, W. FTY720 treatment of kidney transplant patients: A differential effect on B cells, naive T cells, memory T cells and NK cells. Transpl. Immunol. 15, 281-288 (2006).
49. Ljunggren, H.G. & Malmberg, K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 339-339 (2007).
50. Chiesa, S. et al. Multiplicity and plasticity of natural killer cell signaling pathways. Blood 107, 2364-2372 (2005).
51. Walzer, T., Arpin, C., Beloeil, L. & Marvel, J. Differential in vivo persistence of two subsets of memory phenotype CDB T cells defined by CD44 and CD122 expression levels. J. Immunol. 168, 2704-2711 (2002).